SIGNIFICANCE OF BASELINE ACE ACTIVITY IN PATIENTS WITH METABOLIC SYNDROME WHEN ADMINISTRATION OF ACE INHIBITORS AND IMIDAZOLINE AGONISTS IS CONSIDERED

MLA

T. V. Aparina, et al. “Significance of Baseline Ace Activity in Patients with Metabolic Syndrome When Administration of Ace Inhibitors and Imidazoline Agonists Is Considered.” Российский Кардиологический Журнал, no. 2, Apr. 2001, pp. 32–37. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.73a41fce2374e3880d2956c525b871a&authtype=sso&custid=ns315887.

APA

T. V. Aparina, A. N. Britov, E. A. Dilakyan, V. A. Metelskaya, & O. A. Gomazkov. (2001). Significance of Baseline Ace Activity in Patients with Metabolic Syndrome When Administration of Ace Inhibitors and Imidazoline Agonists Is Considered. Российский Кардиологический Журнал, 2, 32–37.

Chicago

T. V. Aparina, A. N. Britov, E. A. Dilakyan, V. A. Metelskaya, and O. A. Gomazkov. 2001. “Significance of Baseline Ace Activity in Patients with Metabolic Syndrome When Administration of Ace Inhibitors and Imidazoline Agonists Is Considered.” Российский Кардиологический Журнал, no. 2 (April): 32–37. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.73a41fce2374e3880d2956c525b871a&authtype=sso&custid=ns315887.